内容紹介
A Case of Recurrent Gastric Cancer Successfully Treated with S-1 Oral Administration
Summary
This report describes a case of recurrent gastric cancer successfully treated with S-1 oral administration. A 77-year old female patient underwent distal gastrectomy for gastric cancer, followed by adjuvant chemotherapy with tegafur-uracil(UFT). However, 1 year after surgical resection, recurrence in the lymph node of the hepatic hilum was diagnosed by abdominal computed tomography. The patient was treated with S-1 alone after refusing intravenous infusion chemotherapy. Three months after treatment, the size of the target lesion decreased significantly, and a complete response was seen on imaging examination during the 2 years of chemotherapy treatment. One year and 5 months after the discontinuation of chemotherapy, recurrence was noted again. Although supportive care was eventually provided to the patient, S-1 oral administration was resumed that resulted in tumor growth control for>6 months. In this patient, S-1 treatment was effective in tumor growth suppression without deteriorating the patient's quality of life(QOL). Further studies are needed to identify patients for whom S-1 therapy is optimal treatment.
要旨 胃癌再発に対して,S-1内服が著効した1例を経験したので報告する。患者は77歳,女性。胃癌に対する幽門側胃切除後にUFTによる術後補助化学療法を行った。術後約1年後に肝門部リンパ節再発を認めたが,静脈内投与による化学療法を希望しなかったためS-1単独療法を行った。内服開始から約3か月後の腹部CTでは肝門部腫瘤が著明に縮小し,6か月後にはCRが得られたため約2年間のS-1内服を継続した。S-1内服を中断してから約1年5か月後に再発を認めたが,S-1内服を再開することで約6か月間腫瘍増大による症状出現を抑制することが可能であった。本症例ではS-1内服加療が非常に有効で,緩和主体の治療へ移行するまで長期間にわたり高いquality of life(QOL)を保つことが可能であった。今後,どのような患者にとってS-1単独療法が好ましい治療法となり得るか検討が必要と思われる。
目次
Summary
This report describes a case of recurrent gastric cancer successfully treated with S-1 oral administration. A 77-year old female patient underwent distal gastrectomy for gastric cancer, followed by adjuvant chemotherapy with tegafur-uracil(UFT). However, 1 year after surgical resection, recurrence in the lymph node of the hepatic hilum was diagnosed by abdominal computed tomography. The patient was treated with S-1 alone after refusing intravenous infusion chemotherapy. Three months after treatment, the size of the target lesion decreased significantly, and a complete response was seen on imaging examination during the 2 years of chemotherapy treatment. One year and 5 months after the discontinuation of chemotherapy, recurrence was noted again. Although supportive care was eventually provided to the patient, S-1 oral administration was resumed that resulted in tumor growth control for>6 months. In this patient, S-1 treatment was effective in tumor growth suppression without deteriorating the patient's quality of life(QOL). Further studies are needed to identify patients for whom S-1 therapy is optimal treatment.
要旨 胃癌再発に対して,S-1内服が著効した1例を経験したので報告する。患者は77歳,女性。胃癌に対する幽門側胃切除後にUFTによる術後補助化学療法を行った。術後約1年後に肝門部リンパ節再発を認めたが,静脈内投与による化学療法を希望しなかったためS-1単独療法を行った。内服開始から約3か月後の腹部CTでは肝門部腫瘤が著明に縮小し,6か月後にはCRが得られたため約2年間のS-1内服を継続した。S-1内服を中断してから約1年5か月後に再発を認めたが,S-1内服を再開することで約6か月間腫瘍増大による症状出現を抑制することが可能であった。本症例ではS-1内服加療が非常に有効で,緩和主体の治療へ移行するまで長期間にわたり高いquality of life(QOL)を保つことが可能であった。今後,どのような患者にとってS-1単独療法が好ましい治療法となり得るか検討が必要と思われる。